The latest trading day saw Johnson & Johnson (JNJ) settling at $163.29, representing a -0.21% change from its previous close.

According to an announcement by the pharmaceutical company, Johnson & Johnson (JNJ) will invest over $55 billion in various ...

Bank of America is bullish on Johnson & Johnson and Clorox stocks. Analysts at the firm expect JNJ and CLX to do well amidst ...

Johnson & Johnson (NYSE: JNJ), has broken ground on a $2 billion pharmaceutical manufacturing facility in Wilson, about 50 ...

Johnson & Johnson (NYSE:JNJ) holds one of the longest dividend growth track records in the market, spanning over 62 years.

J&J JNJ announced plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the ...

We recently published a list of Did Jim Cramer Get These 23 Stocks Right?. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim ...

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...

American pharmaceutical giant Johnson & Johnson (JNJ) is boosting its U.S. investments by 25% to more than $55 billion over ...

Johnson & Johnson has laid out plans to raise U.S. investments by 25% to more than $55 billion over the next four years, as a ...

Johnson & Johnson said it is increasing U.S investments to more than $55 billion over the next four years, boosting spending ...

Johnson & Johnson's Tremfya gains FDA approval for Crohn's disease, backed by Phase 3 trial data and demonstrating ...